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INTRODUCTION
Form and function in development depends on patterned
regulation of proliferation and apoptosis. The control of
apoptosis in developing systems is poorly defined, yet is vital
to the understanding of many degenerative and proliferative
diseases. One of the most dramatic examples of apoptosis in
development occurs in the mammary gland during weaning. At
this time lactational epithelial cells are removed by apoptosis
and the tissue is remodelled in preparation for subsequent
pregnancies (Strange et al., 1992). In the mouse, mammary
gland undergoes developmental changes after lactation that
result in tissue with a non-pregnant phenotype within 2 weeks
of removing the suckling pups. The initial triggers for
mammary apoptosis have not been defined, but candidates
include altered availability of survival ligands such as IGF-1
and glucocorticoids, changes in interactions between
mammary cells and their extracellular matrix possibly through
increased matrix metalloproteinase activity, and the continued
presence of apoptosis-inducing factors in milk that would
normally be removed by suckling (Tonner et al., 1997; Feng et
al., 1995; Lund et al., 1996; reviewed in Streuli et al., 1997).
The intracellular mechanism for regulating apoptosis has not
been fully characterised. Several classes of cell-autonomous
proteins have been identified as important mediators of the
apoptosis response. These include membrane receptors, Bcl-2
family proteins, and the cysteine protease family of caspases
(Farrow and Brown, 1996; Jacobson, 1997; Metcalfe and
Streuli, 1997; Green and Kroemer, 1998). The Bcl-2 family is
extensive and consists of pro-apoptotic proteins such as Bax
and Bak and death-suppressors with homologous sequences
such as Bcl-x and Bcl-w (Oltvai et al., 1993; Farrow et al.,
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Epithelial cells within the mammary gland undergo
developmental programmes of proliferation and apoptosis
during the pregnancy cycle. After weaning, secretory
epithelial cells are removed by apoptosis. To determine
whether members of the Bcl-2 gene family could be involved
in regulating this process, we have examined whether
changes in their expression occur during this developmental
apoptotic program in vivo. Bax and Bcl-x were evenly
expressed throughout development. However, expression of
Bak and Bad was increased during late pregnancy and
lactation, and the proteins were present during the time of
maximal apoptotic involution. Thereafter, their levels
declined. In contrast, Bcl-w was expressed in pregnancy and
lactation but was downregulated at the onset of apoptosis.
Bcl-2 was not detected in lactating or early involuting
mammary gland. Thus, the pro-apoptotic proteins Bax, Bak
and Bad, as well as the death-suppressors Bcl-x, Bcl-2 and
Bcl-w, are synthesised in mouse mammary gland, and
dynamic changes in the expression profiles of these proteins
occurs during development.
To determine if changes in Bak and Bcl-w expression
could regulate mammary apoptosis, their effect on cultured
mouse mammary epithelial cells was examined in transient
transfection assays. Enforced expression of Bak induced
rapid mammary apoptosis, which could be suppressed by
coexpression of Bcl-w. In extracts of mammary tissue in
vivo, Bak heterodimerized with Bcl-x whereas Bax
associated with Bcl-w, but Bak/Bcl-w heterodimers were
not detected. Thus, Bak and Bcl-w may regulate cell death
through independent pathways.
These results support a model in which mammary
epithelial cells are primed for apoptosis during the
transition from pregnancy to lactation by de novo
expression of the death effectors Bak and Bad. It is
suggested that these proteins are prevented from triggering
apoptosis by anti-apoptotic Bcl-2 family proteins until
involution, when the levels of Bcl-w decline.
Our study provides evidence that regulated changes in
the expression of cell death genes may contribute to the
developmental control of mammary apoptosis.
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1995; Gibson et al., 1996). These proteins are perceived as a
switches which determine apoptotic cell fate, although their
mode of action is not fully clear. They form homo- and
heterodimers with each other and are able to insert into
intracellular membranes of organelles (Wolter et al., 1997;
Gross et al., 1998). In one model, Bcl-2 proteins regulate
mitochondrial membrane homeostasis and the release of
cytochrome c, which is a cofactor for caspase activation (Kluck
et al., 1997; Vander Heiden et al., 1997; Zou et al., 1997). In
another, pro-apoptotic Bcl-2 family members displace Apaf-
1/Ced-4 from membrane-bound apoptotic inhibitors, thereby
triggering the activation of downstream caspases (Conradt and
Horvitz, 1998; Green and Kroemer, 1998; Adams and Cory,
1998). However, their full regulation is likely to be more
complex since although some pro- and anti-apoptotic Bcl-2
family members form intermolecular interactions with each
other in vivo, genetic evidence indicates that they can act in
independent pathways to promote or repress apoptosis
(Knudson and Korsmeyer, 1997).
Members of the Bcl-2 family are expressed to varying
degrees in different cell types. Characterizing their profile in
individual tissues is therefore essential for understanding the
molecular control of apoptosis in specific developmental
programmes. Common amongst methods to examine
expression of Bcl-2 proteins are the use of cell lines for RNA
and protein analysis and tissue samples for immunochemistry.
However, major problems arise from interpreting such data
since (1) cell lines are adapted to growing in culture and
therefore have altered susceptibility to apoptosis, (2) cancer
lines are often used which have genetically or epigenetically
altered Bcl-2 protein expression profiles, and (3) suitable
immunochemistry reagents are not always available, especially
for studies on mouse tissue. A further approach is the use of
knockout animals, which provides an indirect method for
analyzing gene function within specific tissues, but is not
appropriate in all situations. Mice with homozygous deletions
in Bcl-x are embryonic lethal and those with Bcl-2 or Bax
deletions do not show full gestational development, thus
limiting their usefulness in studying mammary gland apoptosis
(Motoyama et al., 1995; Veis et al., 1993; Knudson et al.,
1995). In addition, the possibility of redundancy within the
family argues that this approach may not reveal all the cell
type-specific functions of each Bcl-2 protein.
To determine whether members of the Bcl-2 family might
be involved in regulating apoptosis during mammary gland
development, we have therefore examined the expression
patterns of six members of this family in mammary tissue of
normal mice in vivo. Our rationale is that by studying these
proteins in vivo, without interference to their expression
patterns by genetic modification or by removing cells from
animals to culture, we would obtain a true picture of the Bcl-
2 protein profiles in development. In addition, few studies have
been undertaken to examine mechanisms of cell death in
mammalian embryonic or postnatal development programmes.
Moreover, a knowledge of individual players within the family
that regulate apoptosis in mammary gland is a prerequisite for
determining mechanisms of dysregulated survival in breast
cancer.
Little is known of the Bcl-2 family in the breast although
Bcl-2, Bcl-x and Bax are present (Hockenbery et al., 1991;
Krajewski et al., 1994; Pullan et al., 1996; Zapata et al., 1998),
and two reports have pointed at a functional role for Bax and
Bcl-2 in mammary apoptosis (Heermeier et al., 1996; Jager et
al., 1997). We now find that the pro-apoptotic proteins Bax,
Bak and Bad, as well as the death-suppressors Bcl-x, Bcl-2 and
Bcl-w, are synthesised in mouse mammary gland. Dynamic
changes in the expression profiles of these proteins occur
during development, suggesting that these changes may be
involved in regulating post-lactational apoptosis. Our in vivo
model concurs with culture experiments where we show that
two recently identified members of this family, Bak and Bcl-
w, have opposite roles in the apoptotic control of mammary
epithelial cells. We conclude that the developmental
programme of cell survival in vivo may be determined by
extracellular cues that directly affect the levels and function of
Bcl-2 family members.
MATERIALS AND METHODS
Mice
Mammary tissue from ICR mice (Harlan Olac Ltd., Bicester, UK) was
collected from: (1) 8 week old virgin animals, (2) mice pregnant for
3, 6, 9, 12 and 15 days after detecting a vaginal plug, (3) mice in full
lactation for 9 days, and (4) mice where the pups had been removed
for up to 12 days following a 9 day lactation period. RNA was
prepared immediately and the rest of the tissue stored in liquid
nitrogen for subsequent DNA and protein analysis. Three independent
sets of tissues were used for these studies: (1) tissue from a single
mouse at each developmental stage, (2) tissue pooled from three mice
at each stage, and (3) tissue pooled from up to six mice at each stage.
For every experiment, the results for each tissue set were virtually
identical.
For the estrous cycle studies, 6-7 week old virgin ICR mice were
staged at the same time each day for 2 weeks. This involved gently
inserting the tip of a plastic pastette loaded with a small volume of
PBS into the vagina, triturating several times to remove vaginal cells
and examining the cellular composition after Methylene Blue
staining. Once the animals had been demonstrated to be cycling
regularly and a specific stage of the cycle had been unequivocally
determined, one abdominal mammary gland was removed for whole-
mount analysis and the other glands were snap-frozen and stored in
liquid nitrogen. Two independent sets of tissues were used, each of
which produced similar data.
Whole-mount preparation
Abdominal mammary glands were spread flat onto a microscope slide,
briefly dried and fixed overnight in Telly’s Fixative (70% ethanol, 5%
formalin and 5% glacial acetic acid). The glands were defatted with
three washes in 100% acetone (1 hour) before rehydrating through
100% and 95% ethanol. Cell nuclei were stained with 0.08%
Haematoxylin (2 hours) before ‘blueing’ the stain with tap water. The
glands were slightly destained to improve contrast using 50% ethanol
acidified with 0.025 M HCl, dehydrated through 70%-100% ethanol
(4 hours) and cleared with 50% methyl salicylate/50% ethanol, then
100% methyl salicylate. Photomicrographs were taken on Kodak
Ektachrome 160T film using a Leica dissecting microscope.
Cell culture
Cell culture experiments were performed with first passage mammary
epithelial cells from 14.5-18.5 day pregnant ICR mice, as described
previously (Pullan et al., 1996). M1 murine myeloid leukaemia cells
were cultured in DMEM medium (Life Technologies Ltd)
supplemented with 10% heat-inactivated fetal calf serum (Advanced
Protein Products, Brierly Hill, UK). FSK-7 cells (Kittrell et al., 1992)
were cultured in DMEM:F12 medium (Life Technologies)
supplemented with 2% heat-inactivated fetal calf serum.
A. D. Metcalfe and others
1773Developmental regulation of apoptosis in breast
Analysis of DNA integrity
DNA was extracted from glands isolated at different stages of mammary
development (Pullan et al., 1996). Tissues were ground to a powder in
liquid nitrogen and were gently homogenized in 100 mM NaCl, 10 mM
EDTA, 300 mM Tris, 200 mM sucrose, pH 8.0, SDS was added to
0.65% before incubation for 30 minutes at 60°C. Proteinase K
(Boehringer-Mannheim) was added to 500 m g/ml and the sample
incubated for 1 hour at 55°C. Potassium acetate was added to 500 m g/ml
and the sample placed on ice for 30 minutes. Following centrifugation
at 6000 rpm (4000 g) for 15 minutes (4°C), the supernatant was
extracted three times with phenol:chloroform:isoamylalcohol (25:24:1),
then chloroform:isoamylalcohol (24:1), and the DNA was precipitated
with cold absolute ethanol. The DNA was dissolved in 50 m l TE buffer
(10 mM Tris, 1 mM EDTA), pH 8.0 and treated with 5 m g DNAse-free
RNAse (Sigma) for 30 minutes at 37°C. Following further phenol
extraction and ethanol precipitation, equal amounts of DNA were
separated on 2% agarose gels, stained with ethidium bromide and
photographed.
Northern blotting
Total RNA was prepared as described previously (Streuli and Bissell,
1990). Electrophoresis of RNA was performed using the
formaldehyde method (Sambrook et al., 1989) and RNA was
transferred to Hybond-N membranes, which were probed with 32P-
labelled or DIG-labelled (Boehringer Mannheim) cDNA fragments.
The blots were probed and subsequently washed with 0.5· SSC, 0.2%
SDS at 68°C, and exposed either to Kodak XAR film, or to Fujix Bas
2000 storage phosphorimaging plates for quantitative analysis. The
probes used were gel-purified cDNA sequences, corresponding to
bases 107-508 of the mouse Bax coding sequence, full-length mouse
Bcl-x coding sequence, a 540 bp PstI fragment of mouse b -casein and
an 18S cDNA probe.
PCR
First-strand cDNA synthesis was performed using the superscript
preamplification system (Life Technologies). 1 m g of DNase I-treated
total mammary gland RNA was mixed with oligo(dT)12-18 primer,
incubated (10 minutes, 70°C) and placed on ice. A reaction mixture
containing dNTPs, DTT, MgCl2 and PCR buffer was mixed with the
RNA/primer mixture before being incubated for 5 minutes at 42°C.
200 units of Superscript II RT was added to the reaction for a further
50 minutes, and the reaction terminated for 15 minutes at 70°C. The
reactions were Rnase H-treated before using them to amplify target
cDNA sequences.
The forward and reverse primers used in the PCR amplification of
the various cDNAs were all derived from mouse primary sequence
except for Bad and Bcl-2, which were from the human sequence.
Nucleotide numbers corresponding to the mouse cDNA sequence
(starting at codon 1) are shown in Table 1, and nucleotides in
parentheses represent the bases within the primers which are different
to those in the mouse sequence.
Details of the cycling parameters for each combination of primers
are given in Table 1. All reactions were carried out for 40 cycles and
then terminated with a 5 minute extension at 72°C followed by a soak
at 4°C. PCR reactions were analyzed on 1.2% agarose gels followed
by ethidium bromide staining.
Antibody preparation
Anti-Bax and anti-Bcl-2 antibodies were prepared by immunizing
rabbits with a synthetic peptide of mouse Bax (residues 44-59) or
mouse Bcl-2 (residues 41-54) coupled to KLH, and IgG from the
resulting serum was affinity-purified on a Bax or Bcl-2 peptide
column. The anti-Bax antibody was affinity-purified on a cyanogen
bromide-peptide coupled column, whereas the anti-Bcl-2 antibody
was purified on an affigel-15-peptide coupled column. In each case,
the specificity of the anti-Bax and anti-Bcl-2 reactions were confirmed
using excess peptide. The anti-Bcl-w and anti-Bcl-x antibodies were
prepared by immunizing rabbits with a fusion protein of GST coupled
to human Bcl-w (residues 1-172) or human Bcl-x (residues 1-233).
IgG from the resulting serum was absorbed on a GST column, and
subsequently affinity-purified on sepharose-conjugated Bcl-w or Bcl-
x columns.
Western blotting
Total cell lysates were prepared from mammary tissue by
homogenisation in NET lysis buffer (150 mM NaCl, 5 mM EDTA, 50
mM Tris, 1% NP40, 0.5 mM PMSF, 20 m M leupeptin, 2 mM
aprotinin, pH 7.4). Samples of lysate were removed for protein
estimation using the BCA assay (Pierce and Warriner, Chester, UK).
Equal amounts of cell protein (20 m g) were separated by SDS-PAGE
under reducing conditions. Gels were either stained with Coomassie
Brilliant Blue to confirm equal loading of cell proteins, or were
transferred to Immobilon-P membrane (Millipore UK Ltd., Watford,
UK). Membranes were blocked with 5% skimmed milk (Marvel) in
PBS (overnight, 4°C) and incubated (2 hours, RT) with 1.4 m g/ml
rabbit anti-Bax, 2 m g/ml mouse anti-Bak (Calbiochem, monoclonal
antibody #AM03), 1:250 mouse anti-Bad (Transduction Laboratories,
monoclonal antibody #B31420), 1:500 mouse anti-Bcl-x
(Transduction Laboratories, monoclonal antibody #B22620), 2 m g/ml
rabbit anti-Bcl-2 or anti-Bcl-w, or 1:1000 dilution of a monoclonal
antibody to b -casein. Detection was achieved with horseradish
peroxidase-conjugated sheep anti-rat IgG, sheep anti-mouse IgG or
donkey anti-rabbit IgG (Amersham International, plc), followed by
enhanced chemiluminescence detection ( ECL, Amersham).
Immunoprecipitation and GST interaction studies
Tissue samples were extracted in NET lysis buffer (see above) and the
protein content estimated as above. 100-1000 m g of cell protein in 500
m l NET lysis buffer including protease inhibitors (as above) was
precleared of endogenous mouse IgG by incubation with 50 m l Protein
A sepharose beads (1 hour, 4°C, Zymed) and centrifuged to pellet the
beads (10 seconds). The purified antibodies raised against Bax, Bak,
Bcl-x and IgG were immobilized onto CNBr-activated Sepharose 4B
at 1 mg protein/ml packed beads. 20 m l bead-antibody complex was
Table 1. Primer sequences used in the PCR amplification of various cDNAs
cDNA Accession number Forward primer Reverse primer Product
m Bax L22472 1-ATGGACGGGTCCGGGGAGC-19 579-TCAGCCCATCTTCTTCCAGAT-559 579 bp
m Bak Y13231 345-TTTAAGAGTGGCATCAGC-362 625-CATGATCTGAAGAAGAATCTGTG-602 280 bp
hu Bad U66879 360-GAAGGGATGG(G)GGAGGAGC-378 577-CGATCCCACCAGGACTGGA-559 217 bp
hu Bcl-2 M14745 1-ATGGCGCACGCTGGGAGAA-19 720-TCACTTGTGGCCCAGATAGGC-699 720 bp
m Bcl-x X83574 1-ATGTCTCAGAGCAACCGGGAG-21 557-TTTCCGACTGAAGAGTGAGCC-537 557 bp
m Bcl-w U59746 1-ATGGCGACCCCAGCCTCGGCCC-22 579-CTTGCTAGCAAAAAAGGCCCC-559 579 bp
rps29 L31609 100-CTGATCCGCAAATACGGG-117 233-GCATGATCGGTTCCACTTG-215 134 bp
Each combination of primers had specific cycling parameters: Bax: 94°C, 1 minute; 60°C, 30 seconds; 72°C, 2 minutes; Bak: 94°C, 1 minute; 53°C, 30
seconds; 72°C, 1 minute; Bad: 94°C, 1 minute; 58°C, 30 seconds; 72°C, 1 minute; Bcl-2: 94°C, 1 minute; 50°C, 30 seconds; 72°C, 2 minutes; Bcl-x: 94°C, 1
minute; 55°C, 30 seconds; 72°C, 2 minutes; Bcl-w 94°C, 1 minute; 55°C, 30 seconds; 72°C, 1 minute; rps29: 94°C, 1 minute; 55°C, 30 seconds; 72°C, 1 minute.
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added to the precleared tissue lysate and gently vortexed (2 hours,
4°C). The beads were then washed three times in 50 mM Tris-HCl,
pH 8.0, before the bound protein was eluted from the beads with 50
mM diethylamine, pH 11.5. The eluted protein was mixed with
sample buffer before loading. Samples were separated on 12.5% gels,
transferred to Immobilon-P membranes and immunoblotted as above.
For the GST-interaction studies, 100 m g of cell lysate was mixed with
GST-Bcl-w activated beads (1 mg, 2 hours, 4°C). Immune complexes
were washed in lysis buffer and finally resuspended in sample buffer.
Precipitated proteins were separated by SDS-PAGE under reducing
conditions on 12.5% gels and western-blotted as above.
Transfection
Transient transfections were carried out with a mammalian inducible
dual-vector system based on the steroid hormone ecdysone
(Invitrogen, ecdysone-inducible expression kit). The expression
vectors pINDBak, pINDantisenseBak, pINDBclw and
pINDantisenseBclw were constructed by ligating an empty pIND
vector to full-length human Bak or Bclw cDNA in either the sense
and antisense orientations. Sequences were confirmed using the dye-
terminator sequencing kit and an ABI sequencer (according to the
manufacturer’s recommendations; Perkin-Elmer Applied Biosystems;
Warrington, UK). After cotransfection with pINDBak,
pINDantisenseBak, pINDBclw or pINDantisenseBclw and pVgRXR
(which expresses the heterodimeric ecdysone receptor), the
transfected cells were stimulated by treatment with the synthetic
ecdysone analogue, Muristerone A.
FSK-7 cells were seeded at a density of 7.5· 104 cells/cm2 on
coverslips coated with 0.2 m g/ml fibronectin. After reaching 60%
confluence, the coverslips were transferred to 12-well dishes
containing 1 ml of serum-free medium. Lipofectamine (Life
Technologies) was used in the cotransfection of the plasmids
pVgRXR and pINDBak (sense and antisense). Equal amounts of the
two different plasmids, ranging from 0.6 m g to 5 m g, were
cotransfected into FSK-7 cells using 10 m g Lipofectamine in a final
volume of 600 m l serum and antibiotic-free medium (according to the
manufacturers’ recommendations). For the Bak versus Bclw titration
experiment the amount of sense pINDBak was maintained at 2 m g
whilst the amount of pINDBclw (sense and antisense) ranged from
1.25-10 m g. In each case, transfection was carried out for 5 hours
before replacing the transfection mixture with 2 ml serum-containing
medium. The cells were allowed to recover for 16 hours before
washing and incubating with medium containing 10 m M Muristerone
A for a further 20 hours. Wells were washed in PBS and apoptosis of
the detached cells was assessed after fixing cells in 2%
paraformaldehyde in PBS, staining with 4 m g/ml Hoechst 33258, and
examining nuclear morphology using fluorescence microscopy.
RESULTS
Apoptosis in ICR mice occurs at the lactation-
involution interface
Profound remodelling events occur in the mammalian breast
during the pregnancy cycle. The developmental programme of
involution involves removal of lactational alveoli by apoptosis,
combined with remodelling of the tissue to produce a naked
branched ductal network characteristic of the non-pregnant
animal (Fig. 1A). In all our studies, involution of mouse
mammary gland was induced by pup removal after full
lactation had been established over 9 days. In ICR mice this
resulted in apoptosis within 1 day of weaning, remaining
maximal until day 3 when the extent of apoptosis as assessed
by DNA laddering began to decline (Fig. 1B). No
fragmentation of the DNA could be detected in virgin, pregnant
or lactating tissue, nor could it be seen in tissue that had largely
remodelled at involution day 12, even after the use of Southern
blotting to increase the sensitivity of detecting DNA ladders
(data not shown). The kinetics of apoptosis in ICR mice are
therefore different to those in other strains including Swiss and
Balb/c, which have a slower onset of tissue remodelling
(Strange et al., 1992; Lund et al., 1996).
Altered expression of Bax, Bak and Bad during
involution correlates with apoptosis
To determine whether changes in the expression of Bcl-2
related genes might be involved with the induction of
mammary apoptosis, we examined their mRNA and protein
A. D. Metcalfe and others
Fig. 1. Apoptosis in ICR mice occurs at the lactation-involution interface. (A)Whole mounts of mammary gland at different times of
development stained with Haematoxylin show the ductal structures in 8 week virgin mice (V8) and the extent of proliferation after 12 days of
pregnancy (P12) and 9 days of lactation (L9). Regression of the tissue is visible by day 2 of involution (I2) and extensive by day 5 (I5). (B) 5 m g
genomic DNA extracted from the same developmental samples was subjected to agarose gel electrophoresis. Apoptotic DNA ladders appear
within 1 day of involution and are maximal for the next 2 days. Apoptosis subsequently continues but is less extensive on day 4 and 5 and is
largely absent by day 12.
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Fig. 2. High levels of pro-apoptotic Bcl-2 proteins during
involution correlate with apoptosis. (A,B) Total RNA was
prepared from mammary gland for northern analysis. (A) 10 m g
total RNA was blotted onto nylon membranes and hybridised with
32P-labelled mouse Bax and Bcl-x cDNA. Analysis of b -casein
mRNA confirmed that the samples expressed the expected temporal pattern of milk protein genes and an 18S DNA probe was used to assess
equal loading of the gels. (B) The blots were analyzed using storage phosphor imaging plates and a Fujix Bas 2000 bioimaging analyzer. The
levels of specific mRNA were plotted after normalizing to the level of 18S rRNA. (C) RT-PCR of the cell death genes Bax, Bak and Bad
confirmed the RNA profile of Bax as measured by northern blotting and indicated that expression of Bak and Bad were also regulated during
development. A 29S ribonuclear protein (rps29) PCR analysis was included to ensure that equal concentrations of RNA were present in the PCR
reactions. C, control with no cDNA in the PCR reaction. The faster migrating band in Bak PCR reactions was cloned and sequenced and found to
be unrelated to Bak. (D) Multiple bands observed in the involuting day 2 sample of the PCR reaction for Bax were cloned and sequenced. The
centrally migrating band corresponded to the major Bax transcript Baxa, while the faster migrating band corresponded to the transcript for Baxg ,
which lacks exon 2. The slower migrating band contained a sequence which was unrelated to Bax. (E,F) Whole tissue lysates were prepared from
the developmental samples and subjected to polyacrylamide gel electrophoresis. (E) Coomassie staining showed that the protein samples were
equally loaded. Western blotting indicated that b -casein was detected in late pregnancy, lactation and early involution, as expected. (F) Similar
blots were incubated with antibodies directed against Bax, Bak and Bad. Confirmation of the Bax expression profile was validated using a second
independently derived antibody directed against Bax (data not shown). An equal amount of protein from M1 murine myeloid leukaemia cells was
included as a positive control for identification of the Bax protein. In each case, and in the subsequent figures, tissue was isolated from 4, 6, or 8
week virgin (v) mice, and at the indicated number of days of pregnancy (P), lactation (L) and involution (I).
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levels at different stages of development. Initially we looked at
the pro-apoptotic regulators, Bax, Bak and Bad. Northern blot
analysis indicated that Bax mRNA levels were upregulated at
the onset of involution, with the biggest increase in expression
occurring at the lactation-to-involution interface (Fig. 2A,B).
In contrast to the results obtained at the mRNA level, we did
not observe an increase of Bax protein levels in western blots
using anti-mouse Bax antibodies (Fig. 2E,F). However, when
we examined the level of Bax mRNA by RT-PCR, we found
that additional Bax mRNA species were present on days 1 and
2 of involution (Fig. 2C), possibly explaining the increased
level of Bax mRNA detected by northern blotting. Three PCR
products identified at this time point were cloned and
sequenced (Fig. 2D). As expected the 579 bp product
corresponded to mouse Baxa . The slower migrating band did
not contain any sequence homologous to Bax, although
interestingly, the lower molecular mass product was Baxg
(Oltvai et al., 1993), which has not previously been identified
in vivo. The transcript of Baxg results in a protein of approx.
5 kDa due to removal of exon 2 and a shift in reading frame,
but it was not recognized by two different anti-amino-terminal
Bax antibodies and may therefore not contribute to apoptosis
itself (data not shown). However, the presence of this unusual
spliced Bax mRNA indicates that mammary involution is not
only associated with increased transcription of cell death-
promoting genes but also with de novo splicing events, which
could potentially generate novel apoptotic proteins.
A number of cell-death-inducing proteins homologous to
Bax have recently been cloned but have not previously been
examined in mouse mammary gland. RT-PCR revealed an
increase in the expression of Bak mRNA in late pregnancy,
which was retained until the end of the maximum peak of
apoptosis in involution (Fig. 2C). The induction of Bak mRNA
expression was reflected by enhanced levels of Bak protein in
lactation and early involution (Fig. 2F). Similar results were
obtained with Bad at the mRNA and protein levels (Fig. 2C,F).
However, the levels of Bad protein were not completely
comparable to the RNA levels, suggesting that Bad protein may
be subject to more rapid turnover than its mRNA.
Our data show that the cell-death promoting genes, Bax, Bak
and Bad are all expressed during mammary involution, thus they
may act as potential inducers of apoptosis. Since the protein
products of all three of these genes were present at high levels in
lactation, it is possible that apoptosis is primed to occur towards
the end of pregnancy or during lactation but is suppressed by the
expression or activity of cell survival genes until involution.
Downregulation of Bcl-w in mammary epithelial cells
during the transition from lactation to involution
coincides with the induction of apoptosis
We next addressed whether expression of the cell death-
suppressing genes, Bcl-x, Bcl-2 and Bcl-w was also regulated
during mammary gland development. Bcl-x levels were not
significantly altered. There were some fluctuations at the RNA
level as measured by northern blotting (Fig. 2A,B) and RT-
PCR (Fig. 3A), and in levels of Bcl-x protein expression (Fig.
3B), however this death suppressor was always present. In
contrast to another study (Heermeier et al., 1996), we found no
evidence for the expression of Bcl-xS, an alternatively spliced
death-promoting variant of Bcl-x, in mammary gland
involution by either PCR or western blotting (data not shown).
Bcl-2 and Bcl-w, on the other hand, were modulated through
development. Significantly, their expression was
downregulated in involution during the period of maximal
apoptosis (Fig. 3A,B). Bcl-2 was absent when tested by both
RT-PCR and western blotting in lactation and the first 2 days
of involution, although it returned at the later stages of
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Fig. 3. Downregulation of death-suppressing Bcl-2 proteins
coincides with the induction of apoptosis. (A) RT-PCR analysis of
Bcl-x, Bcl-2 and Bcl-w confirmed the RNA profile of Bcl-x as
measured by northern blotting and showed that expression of Bcl-2
and Bcl-w were regulated during development. In several
independent experiments, the Bcl-2 RT-PCR product was absent in
lactation and expressed at low levels in involution, whereas the Bcl-w
RT-PCR product was dramatically lower in the I1 and I2 samples
than L9 but was not completely absent. (B) Whole tissue lysates
were prepared from the developmental samples, separated by
polyacrylamide gel electrophoresis, then analyzed by western
immunoblotting. Blots were incubated with antibodies directed
against Bcl-x, Bcl-2 and Bcl-w. Confirmation of the Bcl-w
expression profile was validated using two additional and
independently derived antibodies directed against Bcl-w (data not
shown). Lysates from M1 cells were included as controls. (C) Whole
tissue lysates were prepared from ICR mice in pregnancy (P12) and
involution (I2) and directly compared with tissue lysates from brain,
mammary gland and uterus of ROSA41 Bcl-w null mutant animals
( - /- ) and their wild-type littermates (+/+) (Ross et al., 1998).
Western blotting confirmed the identity of the detected protein as
Bcl-w.
Bcl-w
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involution during mammary gland remodelling. This agrees
with previous data where we showed that Bcl-2 was expressed
in the epithelial cells of mammary ducts but not in lactational
alveoli (Pullan et al., 1996). Bcl-w is a novel cell survival gene,
homologous to Bcl-2, which is found in a number of tissues
(Gibson et al., 1996). It has been shown to have a role in
controlling testis development (Ross et al., 1998; Print et al.,
1998). We found that Bcl-w mRNA was present in the
mammary gland and was expressed in late pregnancy and
lactation, but levels decreased at the onset of involution (Fig.
3A), at which time its protein was low to undetectable (Fig.
3B). Since Bcl-w has not previously been examined in many
tissues by western blotting, we confirmed our results using two
independently derived antibodies to Bcl-w and obtained
comparable data with each (data not shown). In addition, we
validated the specificity of our antibody by showing that the
band it recognized in western blots was absent in Bcl-w null
mutant mice (Fig. 3C).
These studies show that the apoptosis-suppressors Bcl-2 and
Bcl-w are downregulated during the involution process, and
upregulated after the initial remodelling events have occured.
Their absence at days 1 and 2 of involution may therefore
contribute to the induction of mammary apoptosis. 
Together, our results indicate that the levels of both pro-and
anti-apoptotic Bcl-2 family proteins are altered at different
times during mammary gland development in vivo, and suggest
that changes in the overall balance of cell death regulators may
affect apoptotic outcome during this developmental processs
(Fig. 4). It is noteworthy that all three anti-apoptotic proteins
along with Bax and low levels of Bak are present in virgin and
midpregnant tissue, whereas the situation is reversed during
maximal apoptosis in involution with all three pro-apoptotic
proteins and only Bcl-x being expressed.
The profile of Bcl-2 family proteins in purified
mammary epithelial cells reflects their levels in
lactating mammary gland
To determine whether the profile of Bcl-2 family proteins
detected in vivo was representative of their expression in the
epithelial cell compartment of mammary tissue, we examined
their expression in primary cell culture. Luminal epithelial cells
from late pregnant mammary gland were isolated, separated
from the majority of myoepithelial and stromal cells (Pullan and
Streuli, 1996), and cultured in an environment where the cells
progress from a late pregnant to a lactating phenotype (Aggeler
et al., 1991). In this model b -casein synthesis increased over
several days, and in the most differentiated cells the expression
profile of Bcl-2 family protein was similar to that in lactating
mammary gland (Fig. 5; compare to L9 samples in Figs 2F, 3B
and summary in Fig. 4).
Altered expression of Bcl-2 family proteins in
mammary apoptosis during the estrous cycle
Further evidence in support of the hypothesis that changes in
the expression of cell death regulators influence mammary
epithelial apoptosis was provided by an additional
developmental model. Female mice undergo an estrous cycle,
characterized by four main stages: diestrus, proestrus, estrus
and metestrus. ICR mice show dramatic structural changes
within mammary gland during this cycle, which can be
visualised in whole mounts (Fig. 6A). Following estrus, there
is proliferation involving the appearance of many small newly
Fig. 4. Schematic representation of changes in the expression profiles
of Bcl-2 family proteins during mammary development in the
pregnancy cycle. Pro-apoptotic proteins are shown in triangles, while
death-suppressors are in circles. More triangles/circles indicate a
higher level of expression. Note that (1) Bcl-2 expression is absent in
lactation and during the time of maximal apoptosis; (2) the death-
promoting molecules Bak and Bad are upregulated at the
pregnancy/lactation interface and are proposed to prime the gland for
apoptosis, while the survival-promoting molecules Bcl-w and Bcl-x
maintain mammary gland integrity during lactation; and (3) Bcl-w is
downregulated in involution and may therefore allow apoptosis
through the action of Bax, Bak and Bad.
Fig. 5. Expression of the Bcl-2 family in an in vitro cell culture
model mimics the late pregnant profile observed in vivo. Whole cell
lysates were prepared from primary mammary epithelial cells
cultured on a basement membrane matrix in the presence of serum
for 2 days then washed and changed to serum-free medium
containing differentiation hormones for 0, 1, 2 or 3 days (Pullan et
al., 1996). Equivalent amounts of cell protein were separated by
polyacrylamide gel electrophoresis, then analyzed by western
immunoblotting. Blots were incubated with antibodies directed
against Bax, Bak, Bad, Bcl-x, Bcl-2, Bcl-w and b -casein, and lysates
from M1 cells are included as controls.
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branched ductal and prealveolar structures at metestrus, in
preparation for a possible pregnancy. In the absence of
conception, this is followed by remodelling of the tissue,
returning the gland to a sparse network of ducts. Remodelling
is accompanied by the characteristic DNA internucleosomal
cleavage that occurs during apoptosis, most prominent at
metestrus but continuing through diestrus (Fig. 6B). Similar
apoptotic changes in estrous cycle have been noted in other
strains of mice, but few show the same degree of
morphological change as ICR mice (Andres et al., 1995). They
have also been demonstrated in human breast during the
menstrual cycle (Anderson et al., 1997).
We examined the levels of Bcl-2 family proteins and found
that Bak was upregulated during the most prominent phase of
apoptosis in metestrus and diestrus (Fig. 6C). The levels of Bax
and Bcl-x did not change significantly, which was similar to
our observations at involution. Bcl-w was expressed at each
stage of the estrous cycle, whereas Bad protein was not
detected at any stage of the cycle. In addition, levels of Bcl-2
were similar through the cycle (data not shown). Thus, changes
in the level of the cell death-promoter Bak, correlate with the
developmental onset of apoptosis during the estrous cycle in
mammary gland.
Induced cell death caused by Bak in cultured
mammary epithelial cells can be rescued by Bcl-w
The results of the in vivo study suggest that increased Bak
expression during mammary gland development might be
causally related to apoptosis in vivo. To test for an apoptotic role
of Bak, we examined its capacity to induce death in cultured
mammary epithelial cells. The FSK-7 cell line was derived from
mouse mammary gland (Kittrell et al., 1992). Sublines of FSK-
7 isolated in our laboratory formed alveolar mammary structures
when cultured on basement membrane substrata, thus showing
an ability to undergo morphological differentiation (S.
Runswick, D. Garrod and C. H. Streuli, unpublished data). On
tissue culture dishes, the cells formed cobblestone monolayers
and displayed very low rates of apoptosis. We demonstrated in
transient transfection assays that Bak induced dramatic apoptosis
of FSK-7 cells (Fig. 7). Transfections with Bak vectors that were
driven by the ecdysone analogue, Muristerone A, resulted in
apoptosis occurring over 20 hours, while antisense Bak
constructs had no effect. We were not able to detect Bak protein
in untransfected FSK-7 cells; however, low levels were
expressed after Bak transfection but only in the presence of
Muristerone A (data not shown). Transfections with increasing
amounts of Bak vector DNA resulted in increasing numbers of
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Fig. 6. Bak is implicated as a cell-death gene during
mammary epithelial apoptosis in the estrous cycle.
(A) Whole mounts of mammary gland of ICR mice at
different times of the estrous cycle stained with
Haematoxylin show the ductal structures in estrus, the
extent of proliferation within 2 days at metestrus, and
the progressive regression of the next few days through
diestrus and proestrus. (B) 5 m g genomic DNA extracted
from mammary gland from the same mice was
subjected to agarose gel electrophoresis. Apoptotic
DNA ladders appear during metestrus (M) and are
absent in proestrus (P) and estrus (E). We did not detect
ladders in the diestrus (D) sample by this method,
possibly because of its lack of sensitivity, although
apoptosis has previously been shown to occur at this
stage of the cycle by in situ methods (Andres et al.,
1995). (C) Whole-tissue lysates were prepared from
mammary gland at different times of the estrous cycle
and subjected to polyacrylamide gel electrophoresis.
Coomassie staining indicates that the levels of protein
were even in each sample (top panel). Similar gels were
transferred to nylon and immunoblotted using
antibodies directed against Bcl-w, Bcl-x, Bax and Bak.
The levels of Bak in estrus correspond to those in the
virgin tissue extracts shown in Fig. 2F, whereas its
increased levels at metestrus correlate with the
induction of apoptosis. Bad could not be detected in
non-pregnant tissue at any stage of the estrous cycle.
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apoptotic cells being released from the monolayer after
induction with Muristerone A. Cells treated identically but
without Muristerone A remained as an intact, confluent
monolayer. The cells which detached in these assays were
quantitated and only those detaching after transfection with the
sense Bak construct showed apoptosis (Fig. 7B). Thus, Bak is
competent to induce apoptosis in cultured mammary epithelia,
supporting our hypothesis that it is a pro-apoptotic protein in
mammary gland in vivo.
Elevated levels of Bak were expressed in lactating mammary
gland in vivo and we hypothesized that expression of the anti-
apoptotic protein Bcl-w might have contributed to the low level
of cell death at this time. We therefore tested whether Bcl-w
could suppress the death-promoting activity of Bak in cultured
mammary cells. FSK-7 cells were transfected with levels of the
sense Bak vector that triggered significant apoptosis. Bcl-w
cotransfected with Bak had a striking and dose-dependent
effect in reducing the extent of Bak-induced cell death (Fig.
8A,B). The inhibitory effect of Bcl-w only occurred when it
was expressed in the sense orientation (Fig 8). 
Thus, Bcl-w is able to rescue mammary cells from Bak-
induced apoptosis. This raises the possibility that its
downregulation at the onset of involution might cause the
induction of apoptosis in vivo.
Bcl-2 family partners for Bak and Bcl-w in the
mammary gland
One of the ways in which Bcl-2 family proteins may regulate
apoptosis is through homo- and hetero-dimerization (Oltvai et
al., 1993). We therefore examined whether Bak and Bcl-w
were able to form physical interactions, thereby possibly
explaining their opposite roles in mammary apoptosis.
Fig. 7. Enforced expression of Bak induces apoptosis in mammary
epithelial cells. Transient cotransfections of pINDBak and VgRXR were
carried out in the mammary epithelial cell line, FSK-7, using an
ecdysone-inducible mammalian expression system. Cells were
cotransfected for 5 hours in serum-free medium before being placed in
serum-containing medium overnight. Bak induction was initiated after
addition of 10 m M Muristerone A (Mur). Non-adherent cells were then
scored for apoptosis by morphological phenotype after Hoechst 33528
staining. (A) Phase photomicrographs taken 41 hours after transfection
indicate the effects of cotransfection of pINDBak, in either sense (+) or
antisense (- ) orientation, together with VgRXR, on FSK-7 cells in the
presence or absence of Muristerone A. Equal amounts of the two
plasmids, as indicated, were used for each transfection. (B) Graph
indicating the number of apoptotic cells released from each 15 mm2
coverslip 41 hours after each transfection. Similar quantitative data were
obtained in each of three separate experiments. These data confirm that in
the presence of Muristerone A, increasing concentrations of the sense Bak
construct lead to an increase in the number of apoptotic cells.
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Fig. 8. Bcl-w potentiates survival in FSK-7 cells undergoing
Bak-induced apoptosis. Transient cotransfections of pINDBak,
pINDBclw and VgRXR were carried out and analyzed as
described in Fig. 7. Bak and Bcl-w induction was initiated after
addition of 10 m M Muristerone A. (A) Phase photomicrographs
were taken 41 hours after transfection, and (B) the number of
apoptotic cells released from each 15 mm2 coverslip was
calculated. Note that the transfections with more sense (+) Bcl-w
vector DNA showed an increase in the cell density of the
monolayer and a corresponding decrease in the number of
released apoptotic cells. The antisense ( - ) Bcl-w construct was
not able to suppress the cell death caused by Bak. In each case,
cells treated identically but without Muristerone A remained in
an intact, confluent monolayer (data not shown). The results are
representative of three separate experiments.
Fig. 9. Binding partners for Bak and Bcl-w in the mouse mammary
gland. (A-C) Equal amounts of tissue extracts from lactating (L9) or
apoptotic involuting (I2) mouse mammary gland were precipitated
with the indicated reagent and the identity of proteins in the
precipitates identified by immunoblotting. In each case samples of
lysate were also included on the same gels as positive controls
(lysate). (A) Immunoprecipitations were performed with sepharose-
conjugated anti-Bak and anti-Bax antibodies or control IgG, and the
proteins were separated by SDS-PAGE and transferred to nylon. The
blots were probed with antibodies to Bak, Bax and Bcl-w. Note that
Bcl-w was not present in Bak immunoprecipitates, but did interact
with Bax. No Bcl-w was seen either in whole cell lysates or the Bax
immunoprecipitates of the I2 sample. (B) Immunoprecipitations with
sepharose-conjugated anti-Bcl-x antibodies were separated by SDS-
PAGE, transferred to nylon, and probed with antibodies to Bcl-x or
Bak. (C) Tissue extracts were mixed with either GST- or GST-Bcl-w
conjugated sepharose beads for 2 hours before centrifugation and
separation by SDS-PAGE The gels were transferred to nylon and
subjected to immunoblotting using antibodies directed against Bak,
Bad and Bax. These data confirm that Bcl-w interacts with Bax but
not Bak or Bad in mammary epithelial cells. Note that the I2 lysate
contains Bax, which is capable of binding GST-Bcl-w, but the
absence of Bcl-w at this developmental stage precludes such an
interaction taking place in vivo.
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Initially we determined binding partners for Bak in mammary
tissue extracts. Anti-Bak antibody was coupled to sepharose and
used to immunoprecipitate Bak from extracts of lactating and
involuting mammary gland. Subsequent immunoblotting
revealed the presence of Bak not Bcl-w (Fig. 9A). However Bak
did interact with Bcl-x, since sepharose-conjugated anti-Bcl-x
immunoprecipitated Bak from mammary extracts (Fig. 9B).
Since Bcl-2 is absent from lactating and involuting mammary
gland (Fig. 3), these results suggest that Bak forms binding
partners with Bcl-x but not Bcl-w at this time of development.
We also examined Bcl-w binding partners in mamary tissue
extracts. Sepharose-conjugated anti-Bax antibody immuno-
precipitated Bcl-w from extracts of lactating mammary gland,
but not from involuting tissue from which Bcl-w was absent
(Fig. 9A). Immunoprecipitation of Bak suggested that there
was no interaction of Bak with Bcl-w (Fig 9A). Finally, a GST-
Bcl-w fusion protein was incubated with mammary gland
lysates, and immunoblots revealed a specific interaction of Bcl-
w with Bax, but not with Bak or Bad (Fig. 9C).
Together, these protein-protein interaction studies show that
Bak and Bcl-w are not binding partners in the mammary gland
in vivo. Given our results from the transfection study, Bak and
Bcl-w may therefore function independently to regulate
apoptosis. This concurs with a new view of apoptosis where
some pro-and anti-apoptotic members of the family, such as
Bax and Bcl-2, have been shown to regulate cell death
independently and do not require interations between them
(Knudson and Korsmeyer, 1997). However, we do find that in
mammary gland Bak/Bcl-x and Bax/Bcl-w heterodimers exist,
supporting a view that apoptosis is controlled through a
balance between these two arms of the Bcl-2 protein family.
DISCUSSION
This study ties together observations on the regulated
expression of Bcl-2 proteins in mammary gland development
in vivo with their ability to induce or suppress apoptosis in
mammary epithelial cells in culture. We demonstrate that Bak,
which is expressed at high levels during lactation and
involution in vivo, can induce apoptosis in culture. In contrast,
Bcl-w, which is expressed during lactation in vivo but is not
present during involution, suppresses the death-promoting
activity of Bak in culture. Our transfection data obtained from
the culture model provide the first evidence that Bcl-w can
functionally antagonize Bak activity.
Our work also demonstrates that apoptosis during
development of the mouse mammary gland in the pregnancy
cycle is associated with changes in the expression levels of Bcl-
2 family proteins. Thus, expression of Bcl-2 proteins is
developmentally regulated in some tissues, indicating a novel
mechanism for the control of apoptosis in development.
Moreover, the control of apoptosis in vivo appears to be
significantly more complex than has been apparent in culture
studies using other cell systems, and involves multiple players.
We favour a model whereby many pro- and anti-apoptotic
regulators hold the survival of a cell in balance, and that their
levels and function are regulated by extracellular signals.
Control of apoptosis by Bcl-2 family proteins in
mammary gland
This leads to the question of what external factors regulate the
expression of Bcl-2 family genes in mammary gland, and
whether they directly impinge on the transcriptional and post-
translational control mechanisms. Although the systemic
hormonal changes regulating progression through estrous and
pregnancy cycles are not the same, altered levels of circulating
steroid hormones or prolactin, and reduced availability of
locally acting survival factors such as IGF-1 or extracellular
matrix, are all candidates for final cues to trigger apoptosis at
the appropriate time (Tonner et al., 1997; Pullan et al., 1996;
Lund et al., 1996). Of these, only steroids have so far been
shown to affect expression of Bcl-2 proteins in mammary cells
(Teixeira et al., 1995; Wang and Phang, 1995; Leung et al.,
1998). Steroid flux is more predominant in controlling the
estrous cycle than involution, and a report that estradiol
suppresses Bak expression in MCF-7 cells may explain our
own observation that the control of apoptosis in the estrous
cycle is different to that in involution (Leung et al., 1998).
The downstream control of apoptosis through Bcl-2 proteins
is still a subject of intense experimentation and speculation.
Whilst changes in the expression of Bcl-2 proteins may provide
a primary mechanism of specifying mammary apoptosis in
vivo, it is probable that alterations in post-translational
modifications, subcellular localization, or protein-protein
interactions fine-tune the timing of apoptosis. Phosphorylation
controls the function of Bad (Datta et al., 1997), but has not so
far been demonstrated for Bax, Bak, Bcl-x or Bcl-w. In
addition the role of phosphorylation in suppressing apoptosis
by Bcl-2 is controversial since mutation studies suggest a
possible requirement for phosphorylation (Ito et al., 1997), but
cell cycle studies show that its phosphorylation is not involved
with apoptosis and correlates instead with mitosis (Ling et al.,
1998). Altered subcellular localization of Bcl-2 proteins,
particularly Bax, has also been proposed to have significance
for apoptosis (Wolter et al., 1997). We have begun a similar
analysis in mammary gland in vivo, and preliminary
experiments indicate that Bak may move from cytosol to a
membrane fraction in involution (A. Metcalfe and C. H.
Streuli, unpublished data).
Separate Bcl-2 family pathways may regulate
survival in mammary gland
Notwithstanding these possible changes, it is still unclear to
what extent Bcl-2 proteins regulate apoptotic progression
through heterodimerization between opposing members of the
family (Yin et al., 1994). Whilst some members of the family
can interact in vivo and in vitro, there is now substantial
evidence that death promoters and suppressors can control
apoptosis independently of each other. For example, genetic
evidence from doubly-deficient Bax/Bcl-2 mice indicates that
these proteins function independently in the control of
apoptosis (Knudson and Korsmeyer, 1997). In addition,
mutations in Bcl-x that block its ability to bind Bax or Bak still
protect against viral-induced apoptosis (Cheng et al., 1996),
and a mutant form of Bcl-2 which does not bind Bax protects
T cells from apoptosis in a transgenic mouse model (St Clair
et al., 1997). Moreover, the anti-apoptotic function of Bcl-2
and Bcl-x can be opposed by Bak in the absence of any
heterodimerization (Simonian et al., 1997).
One possible explanation for these findings is that the
regulation of cell death involves many members of the Bcl-2
family. This in turn suggests that the precise expression profile
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needs to be defined for each cell type and taken into account
when trying to interpret apoptotic mechanism. Examination of
expression of a wide range of Bcl-2 proteins during the
development of mammary gland suggests that many members
of the family may be involved in regulating survival and
apoptosis. The results of our culture study with mammary
epithelial cells suggest that Bcl-w can protect against the
apoptotic properties of Bak. However, our inability to
demonstrate a physical interaction between Bcl-w and Bak in
either tissue extracts or in vitro studies with GST fusion
proteins indicates that any functional role they may have in
vivo is through independent pathways. Indeed, the existence of
Bak/Bcl-x and Bax/Bcl-w heterodimers in mammary tissue
suggests the presence of two separate pathways working in
concert to control survival in the normal gland. One possible
advantage of such a system may be to ensure that aberrant
apoptosis does not occur in the event of one gene being
mutated or lost.
A hypothesis for the intracellular control of
apoptosis in normal mammary gland
The results obtained from expression studies in vivo and
functional experiments in culture lead to a hypothesis for the
intracellular control of apoptosis in normal mammary gland.
We suggest that involution is primed in lactation through the
expression of Bak. However, sufficient Bcl-x and Bcl-w are
present at this time to suppress its killing effects. When
involution is stimulated following pup removal, the reduced
levels of Bcl-w may alter the balance of pro-and anti-apoptotic
regulators in favour of Bak- and Bax-mediated killing. The
absence of Bcl-2 may also contribute to the potential of
mammary cells to undergo apoptosis after lactation.
Furthermore, the presence of Bad may also have a pro-
apoptotic role, but confirmation of this possibility awaits
further experimentation. A role for Bax in regulating
susceptibility to apoptosis in human breast has been suggested
following observations that its level is lower in many breast
carcinomas (Krajewski et al., 1995; Bargou et al., 1995). Based
on our study, it may now be more pertinent to compare the
relative Bax/Bcl-w and Bak/Bcl-x ratios in normal and tumour
tissue from patients with breast cancer as possible prognostic
indicators of survival to this disease.
Conclusion
In summary, we have examined Bcl-2 family proteins in an in
vivo model for apoptosis and demonstrate that they are
regulated during mammary gland development. Their
expression patterns correlate with the ability of specific
members of this family, Bak and Bcl-w, to trigger or suppress
apoptosis in cultured mammary cells. Our data from protein
interaction studies of extracts from mammary tissue in vivo
support the concept that some pro- and anti-apoptotic members
of the Bcl-2 family control apoptosis independently.
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